AnaptysBio's asthma therapy improves eosinophil count and lung function in Phase IIa

AnaptysBio Inc. (NASDAQ:ANAB) reported interim data from a Phase IIa trial to treat severe eosinophilic asthma showing that etokimab (formerly ANB020) improved eosinophil count and

Read the full 256 word article

User Sign In